


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of the formula I



in which

- R^1 and R^2 are each, independently of one another, H, A, OH, OA or Hal,
 R^1 and R^2 together are alternatively alkylene having 3-5 carbon atoms, -O-CH₂-CH₂-,
-CH₂-O-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-,
 R^3 and R^4 are each, independently of one another, H or A,
X is R^5 , R^6 or R^7 monosubstituted by R^8 ,
 R^5 is linear or branched alkylene having 1-10 carbon atoms, in which one or two CH₂
groups are optionally replaced by -CH=CH- groups, O, S or SO,
 R^6 is cycloalkyl or cycloalkylalkylene having 5-12 carbon atoms,
 R^7 is phenyl or phenylmethyl,
 R^8 is COOH, COOA, CONH₂, CONHA, CON(A)₂ or CN,
A is alkyl having from 1 to 6 carbon atoms, and
Hal is F, Cl, Br or I,
or a physiologically acceptable salt thereof.


2. (Previously Presented) A compound of the formula I according to Claim 1 that is selected from the group consisting of

- (a) 5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]pentanoic acid;

- (b) 4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]benzoic acid;
 - (c) 4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]butyric acid;
 - (d) 5-[7-(benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]pentanoic acid;
 - (e) [7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-ylmethoxy]acetic acid;
- and a physiologically acceptable salt thereof.

3. (Previously Presented) A process for preparing a compound of the formula I according to Claim 1 or a salt thereof, comprising

- a) reacting a compound of the formula II




in which

R^3 , R^4 and X are as defined in Claim 1,

and L is Cl, Br, OH, SCH₃ or a reactive esterified OH group,

with a compound of the formula III



in which

R^1 and R^2 are as defined above, or

- b) converting a radical X in a compound of the formula I into another radical X by hydrolysing

an ester group to a COOH group or converting a COOH group into an amide or into a cyano group and/or converting a compound of the formula I into one of its salts.

4. (Cancelled)

5. (Previously Presented) A pharmaceutical composition, comprising at least one compound of the formula I according to Claim 1 and/or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.

6. (Cancelled)

7. (Cancelled)

8. (Previously Presented) A method of preparing a pharmaceutical composition comprising bringing together a compound according to claim 1 and a pharmaceutically acceptable carrier.

9. (Previously Presented) A method of treating a potency disorder, comprising administering a compound of claim 1 to a patient in need thereof.

10. (Cancelled)

11. (Previously Presented) A method of treating cardiac insufficiency, comprising administering a compound of claim 1 to a patient in need thereof.

12. (Previously Presented) A method of treating erectile dysfunction, comprising administering a compound of claim 1 to a patient in need thereof.

13. (Cancelled)

14. (Cancelled)

15. (Currently Amended) A compound of the formula I according to Claim 1, wherein X is R⁵ monosubstituted by R⁸ ~~substituted by COOH, COOA, CONH₂, CONA₂, CONHA or CN, or is phenyl or phenylmethyl.~~

16. (Currently Amended) A compound of the formula I according to Claim 1, wherein R¹ and R² together are alkylene having 3-5 C atoms, -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-, and X is R⁵ substituted by R⁸ ~~COOH, COOA, CONH₂, CONA₂, CONHA or CN, or is phenyl or phenylmethyl.~~

17. (Currently Amended) A compound of the formula I according to Claim 1, wherein R¹, R², in each case independently of one another, are H, A, OH, OA or Hal, or R¹ and R² together are alkylene having 3-5 C atoms, -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-, and X is R⁵ substituted monosubstituted by R⁸ ~~COOH, COOA, CONH₂, CONA₂, CONHA or CN, or is phenyl or phenylmethyl.~~

18. (Currently Amended) A compound of the formula I according to Claim 1, wherein R¹, R², in each case independently of one another, are H, A, OH, OA or Hal, or R¹ and R² together are alkylene having 3-5 C atoms, -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-, and ~~X is~~ X is alkylene having 2-5 C atoms, which is monosubstituted by R⁸, ~~or cyclohexyl, phenyl or phenylmethyl,~~ R³ is alkyl having 1-6 C atoms, R⁴ is alkyl having 1-6 C atoms, R⁸ is COOH or COOA, A is alkyl having 1 to 6 C atoms, and Hal is F, Cl, Br or I.

19. (Previously Presented) A compound of the formula I according to Claim 1, wherein R¹, R², in each case independently of one another are H, A, OH, OA or Hal, or R¹ and R², together are alkylene having 3-5 C atoms, -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-, R³ is alkyl having 1-6 C atoms, R⁴ is alkyl having 1-6 C atoms, and X is -(CH₂)_{2.5}-R⁸, 4-R⁸-cyclohexyl, 4-R⁸-phenyl or 4-(R⁸-methyl)phenyl.

20. (Currently Amended) A compound of the formula I according to Claim 1, wherein R¹, R², in each case independently of one another are H, A, OH, OA or Hal, R¹ and R² together are also

alkylene having 3-5 C atoms, -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-, R³ is alkyl having 1-6 C atoms, R⁴ is alkyl having 1-6 C atoms, X is -(CH₂)₂₋₅-R⁸, in which one CH₂ group is ~~are~~ optionally replaced by O, or is 4-R⁸-cyclohexyl, 4-R⁸-phenyl or 4-(R⁸-methyl)phenyl, and R⁸ is COOH or COOA.

21. (Previously Presented) A compound of the formula I according to Claim 1, wherein R⁵ is ethylene, propylene, butylene or CH₂-O-CH₂.

22. (Previously Presented) A compound of the formula I according to Claim 1, wherein R⁸ is COOH or COOA.